This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence in a Treatment that’s setting the standard1-3
Primary results from a Phase III trial of IBRANCE® plus fulvestrant compared with fulvestrant alone in women with HR+/HER2- locally advanced and metastatic breast cancer that progressed on previous endocrine therapy.1-3
Study design and patient populations for the Phase III PALOMA-3 Trial
Efficacy outcomes including mPFS, mOS and the impact of prior chemotherapy on IBRANCE® efficacy
EORTC QLQ-C30 Quality of Life outcomes
IBRANCE® Safety Profile and frequently reported adverse events
Real-world patient data for IBRANCE® in advanced breast cancer
AI : Aromatase Inhibitor, EORTC QLQ-C30 : European Organisation for Research and Treatment of Cancer Quality Of Life Questionnaire C30, ET : endocrine therapy, HR+/ HER2- : Hormone Receptor‑Positive/ Human Epidermal Growth Factor Receptor 2-Negative, LHRH : Luteinising Hormone-Releasing Hormone, mOS : Median Overall Survival, mPFS : Median Progression-Free Survival, SmPC : Summary Of Product Characteristics.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021